167414-75-7

Basic information

• Product Name: 3-OXO-3-(1-CBZ-PIPERIDIN-4-YL)-PROPIONIC ACID ETHYL ESTER
• Synonyms: Ethyl 3-(N-Cbz-piperidin-4-yl)-3-oxopropanoate;N-CBZ-4-Piperidinepropanoic acid,beta-oxo-,ethyl ester;Ethyl 3-(N-Cbz-4-piperidyl)-3-oxopropanoate;Ethyl 3-(1-Cbz-piperidin-4-yl)-3-oxopropanoate;Ethyl 3-(1-benzyloxycarbonylpiperidin-4-yl)-3-oxopropanoate;4-Piperidinepropanoic acid, β-oxo-1-[(phenylmethoxy)carbonyl]-, ethyl ester;Benzyl 4-(3-ethoxy-3-oxopropanoyl)
• CAS NO: 167414-75-7
• Molecular Formula: C₁₈H₂₃NO₅
• Molecular Weight: 333.38
• Mol File: 167414-75-7.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 461.8°Cat760mmHg
• Flash Point: 233.1°C
• Appearance: /
• Density: 1.19g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.533
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 10.39±0.20(Predicted)
• CAS DataBase Reference: 3-OXO-3-(1-CBZ-PIPERIDIN-4-YL)-PROPIONIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 3-OXO-3-(1-CBZ-PIPERIDIN-4-YL)-PROPIONIC ACID ETHYL ESTER(167414-75-7)
• EPA Substance Registry System: 3-OXO-3-(1-CBZ-PIPERIDIN-4-YL)-PROPIONIC ACID ETHYL ESTER(167414-75-7)

Safety Data

• Hazardous Substances Data: 167414-75-7(Hazardous Substances Data)

Usage

General Description

3-OXO-3-(1-CBZ-piperidin-4-yl)-propionic acid ethyl ester is a chemical compound used in the pharmaceutical industry as an intermediate in the synthesis of various pharmaceuticals. It is a derivative of 3-oxo acids and piperidine, and it is commonly used as a building block in the production of drugs with analgesic, anti-inflammatory, or antiviral properties. 3-OXO-3-(1-CBZ-PIPERIDIN-4-YL)-PROPIONIC ACID ETHYL ESTER is typically utilized in chemical research and development processes to create new drug candidates with potentially beneficial therapeutic effects. Due to its significance in pharmaceutical synthesis, 3-OXO-3-(1-CBZ-piperidin-4-yl)-propionic acid ethyl ester is an important chemical compound in the field of medicinal chemistry.

InChI:InChI=1/C18H23NO5/c1-2-23-17(21)12-16(20)15-8-10-19(11-9-15)18(22)24-13-14-6-4-3-5-7-14/h3-7,15H,2,8-13H2,1H3

Upstream product

• 6148-64-7 ethyl potassium malonate 
• 10314-98-4 1-benzyloxycarbonylpiperidine-4-carboxylic acid 
• 501-53-1 benzyl chloroformate 
• 498-94-2 isonipecotic acid 
• 141-78-6 ethyl acetate 
• 10314-99-5 benzyl 4-(chlorocarbonyl)piperidine-1-carboxylate 

Downstream Products

• 1115491-17-2 benzyl 4-(2-amino-6-hydroxypyrimidin-4-yl)piperidin-1-carboxylate 
• 1266159-39-0 benzyl 4-(3-amino-4-(4-phenoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-6-yl)-1-piperidinecarboxylate 
• 1266160-29-5 4-(4-phenoxyphenyl)-6-(piperidin-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-amine 
• 1413943-82-4 2-(4-(3-amino-4-(4-phenoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-6-yl)piperidine-1-carbonyl)-3-cyclopropylacrylonitrile 
• 1413943-84-6 benzyl 4-(4-chloro-5-cyano-6-(4-phenoxyphenyl)pyridin-2-yl)piperidine-1-carboxylate 
• 1413943-85-7 3-(4-(3-amino-4-(4-phenoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-6-yl)piperidin-1-yl)-3-oxopropanenitrile 
• 1413943-83-5 benzyl 4-(5-cyano-4-oxo-6-(4-phenoxyphenyl)-1,4-dihydropyridin-2-yl)piperidine-1-carboxylate 

Relevant articles and documents

Pyrazolopyrimidines as Potent Stimulators for Transient Receptor Potential Canonical 3/6/7 Channels

Transient receptor potential canonical 3/6/7 (TRPC3/6/7) are highly homologous receptor-operated nonselective cation channels. Despite their physiological significance, very few selective and potent agonists are available for functional examination of these channels. Using a cell-based high throughput screening approach, a lead compound with the pyrazolopyrimidine skeleton was identified as a TRPC6 agonist. Synthetic schemes for the lead and its analogues were established, and structural-activity relationship studies were carried out. A series of potent and direct agonists of TRPC3/6/7 channels were identified, and among them, 4m-4p have a potency order of TRPC3 > C7 > C6, with 4n being the most potent with an EC50 of 20 nM on TRPC3. Importantly, these compounds exhibited no stimulatory activity on related TRP channels. The potent and selective compounds described here should be suitable for evaluation of the roles of TRPC channels in the physiology and pathogenesis of diseases, including glomerulosclerosis and cancer.

TYROSINE KINASE INHIBITORS

The present disclosure provides compounds and pharmaceutically acceptable salts that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, JAK3, TEC, BTK, and TXK and are therefore useful for the treatment of diseases treatable by

PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS

In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.